Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
2018 ◽
Vol 36
(15_suppl)
◽
pp. 9070-9070
2020 ◽
Vol 21
(5)
◽
pp. e497-e510
◽
2020 ◽
Vol 88
◽
pp. 106907
◽